Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Up 1,315.5% in June

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totaling 67,279 shares, an increase of 1,315.5% from the June 15th total of 4,753 shares. Currently, 4.0% of the company’s shares are sold short. Based on an average daily volume of 201,808 shares, the days-to-cover ratio is currently 0.3 days.

Bone Biologics Stock Up 0.7%

Shares of NASDAQ BBLG traded up $0.01 on Friday, hitting $1.39. The company had a trading volume of 24,135 shares, compared to its average volume of 143,856. The business has a 50 day moving average of $1.32 and a two-hundred day moving average of $1.37. The firm has a market capitalization of $2.50 million, a P/E ratio of -0.61 and a beta of 0.90. Bone Biologics has a 12-month low of $1.05 and a 12-month high of $4.13.

Bone Biologics (NASDAQ:BBLG) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.43). On average, sell-side analysts anticipate that Bone Biologics will post -1.17 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the period. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is currently owned by hedge funds and other institutional investors.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.